Recommended composition of influenza virus vaccines for use in the 2021-2022 northern hemisphere influenza season
26 February 2021
| Meeting report
Overview
26 February 2021
It is recommended that quadrivalent vaccines for use in the 2021 - 2022 northern hemisphere influenza season contain the following:
Egg-based Vaccines
- an A/Victoria/2570/2019 (H1N1)pdm09-like virus;
- an A/Cambodia/e0826360/2020 (H3N2)-like virus;
- a B/Washington/02/2019 (B/Victoria lineage)-like virus; and
- a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus
Cell- or recombinant-based Vaccines
• an A/Wisconsin/588/2019 (H1N1)pdm09-like virus;
• an A/Cambodia/e0826360/2020 (H3N2)-like virus;
• a B/Washington/02/2019 (B/Victoria lineage)-like virus; and
• a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.
It is recommended that trivalent influenza vaccines for use in the 2021 - 2022 northern hemisphere influenza season contain the following:
Egg-based Vaccines
• an A/Victoria/2570/2019 (H1N1)pdm09-like virus;
• an A/Cambodia/e0826360/2020 (H3N2)-like virus; and
• a B/Washington/02/2019 (B/Victoria lineage)-like virus
Cell- or recombinant-based Vaccines
• an A/Wisconsin/588/2019 (H1N1)pdm09-like virus;
• an A/Cambodia/e0826360/2020 (H3N2)-like virus; and
• a B/Washington/02/2019 (B/Victoria lineage)-like virus
WHO Team